New York State Common Retirement Fund Lowers Position in Acelyrin, Inc. (NASDAQ:SLRN)

New York State Common Retirement Fund decreased its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 32.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,512 shares of the company’s stock after selling 7,305 shares during the period. New York State Common Retirement Fund’s holdings in Acelyrin were worth $49,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Franklin Resources Inc. lifted its position in shares of Acelyrin by 36.9% during the 3rd quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock valued at $634,000 after buying an additional 34,642 shares in the last quarter. Virtu Financial LLC purchased a new position in shares of Acelyrin during the 3rd quarter valued at approximately $50,000. Barclays PLC lifted its holdings in Acelyrin by 208.8% in the 3rd quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after purchasing an additional 65,188 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Acelyrin by 30.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after purchasing an additional 388,631 shares in the last quarter. Finally, Public Employees Retirement System of Ohio lifted its holdings in Acelyrin by 54.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 102,347 shares of the company’s stock valued at $505,000 after purchasing an additional 36,154 shares in the last quarter. Hedge funds and other institutional investors own 87.31% of the company’s stock.

Wall Street Analysts Forecast Growth

SLRN has been the topic of a number of research reports. Citigroup decreased their price objective on Acelyrin from $6.00 to $3.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Wells Fargo & Company decreased their price objective on Acelyrin from $15.00 to $13.00 and set an “overweight” rating on the stock in a report on Wednesday, December 11th. Finally, HC Wainwright decreased their price objective on Acelyrin from $8.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, January 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, Acelyrin currently has a consensus rating of “Hold” and a consensus price target of $9.60.

Acelyrin Stock Up 3.5 %

Shares of SLRN opened at $2.66 on Friday. Acelyrin, Inc. has a 52-week low of $1.85 and a 52-week high of $8.70. The company has a market capitalization of $266.87 million, a PE ratio of -1.08 and a beta of 1.25. The stock has a fifty day simple moving average of $2.32 and a two-hundred day simple moving average of $3.97.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.